In this research, it was shown that high expression of DC-STAMP has an adverse effect on the overall survival of AML patients and is linked to both AML-associated pathway activation and special immune cells or checkpoints, which suggests that high expression of DC-STAMP may be a potential independent prognostic factor and an immunotherapeutic target for AML. Here, DCSTAMP is linked to acute myeloid leukemia.